The Technical AnalystExchange: ASX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Cann Group Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0620
America/New_York / 29 feb 2024 @ 00:10
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 27.14 mill |
| EPS: | -0.0700 |
| P/E: | -0.890 |
| Earnings Date: | Jul 25, 2024 |
| SharesOutstanding: | 437.75 mill |
| Avg Daily Volume: | 0.141 mill |
| RATING 2024-02-29 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.890 | sector: PE 1.258 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.890 | industry: PE 38.27 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0570 - 0.0670 ( +/- 8.06%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0620 (0.00% ) |
| Volume | 0.636 mill |
| Avg. Vol. | 0.141 mill |
| % of Avg. Vol | 451.17 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CAN.AX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CAN.AX
Cann Group Limited engages in the breeding, cultivation, production, manufacturing, clinical evaluation, and supplying medicinal cannabis for sale and use within Australia and for overseas export markets. It licenses to undertake research and to cultivate cannabis for human medicinal and research purposes. The company was founded in 2014 and is based in Port Melbourne, Australia.